Home › NDC Lookup › Ingredients › Neomycin Sulfate, Polymyxin B Sulfate An... › 69918-0515-05
👁️image loading
(from DailyMed)

neomycin sulfate, polymyxin b sulfate and dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL Suspension, 5 mL — NDC 69918-515-05 (Billing 69918-0515-05)

by Nordic Pharma, Inc. · 5 mL in 1 BOTTLE, PLASTIC

This is a package of 5 mL of neomycin sulfate, polymyxin b sulfate and dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL Suspension from Nordic Pharma, Inc., marketed since Mar 2025 and currently FDA-listed; retail pharmacies pay about $1.78 per mL (NADAC). It is this product's only package size.

NDC 69918-0515-05
🏷️ FDA NDC (as labeled) 69918-515-05 billing pads the product segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 69918-515-05 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
69918 labeler · 515 product · 05 package
Package marketed since
Mar 31, 2025
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
5 mL per package
Barcode (UPC-A, from the NDC)
3 6991851505 2
Medicaid fills, this package
24,070 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 69918-515-05
Product NDC 69918-515
11-digit billing NDC 69918051505
NCPDP billing unit ML — per mL (volume)
Application # NDA050023
SPL Set ID 34028664-7112-42b9-b6fc-5ed048759680
Established class (EPC) Aminoglycoside Antibacterial; Corticosteroid; Polymyxin-class Antibacterial
Mechanism of action Corticosteroid Hormone Receptor Agonists
Chemical class Aminoglycosides; Polymyxins
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2025-03-31
Route OPHTHALMIC
Dosage form SUSPENSION
Substance NEOMYCIN SULFATE; POLYMYXIN B SULFATE; DEXAMETHASONE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 048547
GCN 14286
HICL code 003523
Ingredient (HICL) Neomycin/Polymyxin B/Dexametha
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6I
Therapeutic class — specific (HIC3) Eye Antibiotic And Glucocorticoid Combinations
AHFS code 08:12.02.00
AHFS class Aminoglycoside Antibiotics
FDB label name NEOMYC-POLYM-DEXAMETH EYE DROP
FDB brand name Neomycin-Polymyxin-Dexameth
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 048547
  • GCN: 14286
  • HICL (First Databank): 003523
  • AHFS class code: 08:12.02.00
Why two NDCs? The FDA registers this code as 69918-515-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 69918-0515-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name NEOMYC-POLYM-DEXAMETH EYE DROP Ingredient Neomycin/Polymyxin B/Dexametha
📖 What it is MedlinePlus · NLM

Dexamethasone reduces the irritation, redness, burning, and swelling of eye caused by chemicals, heat, radiation, infection, allergy, or foreign bodies in the eye. It is sometimes used after eye surgery.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats inflamed eyes when there is a bacterial infection or a risk of one. That includes inflammation of the conjunctiva, cornea and front of the eye, chronic anterior uveitis,...
  • Tilt your head back and pull your lower lid down to make a small pocket. Place about a half inch of ointment there without letting the tube touch your eye. Then look down before cl...
  • Some labels say to shake the suspension well before using it, so check yours. The drops go in the eye only, and the amount and frequency depend on how severe your condition is. Fol...
  • You may notice redness, irritation, or itching if you are allergic to the antibiotic. Steroids can also raise eye pressure and slow healing. Call your doctor if you have eye pain,...
📖 Read our full Dexamethasone / Neomycin / Polymyxin B guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $1.782 $8.91 / 5 ml
Medicaid paysCMS SDUD · 12 mo $3.05 $15.24 / 5 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $1.782 $1.608
▲ Up 2% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
69918-0515-05 You're viewing this Main listing 5 mL in 1 BOTTLE, PLASTIC 2025-03-31 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Neomycin Polymyxin B Sulfates and Dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 24208-0830-60 Bausch 1 bottle $1.782 AT Availability likely —
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 61314-0630-06 Sandoz 5 ml $1.782 AT Availability likely —
neomycin sulfate, polymyxin b sulfate and dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mLthis 69918-0515-05 Nordic 5 ml $1.782 AT Availability likely —
Neomycin Polymyxin B Sulfates and Dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 50090-0570-00 A-S 1 bottle — AT FDA listed —
Neomycin Polymyxin B Sulfates and Dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 63187-0498-05 Proficient 1 bottle — AT FDA listed —
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 68071-3359-05 NuCare 5 ml — AT FDA listed —
Neomycin Polymyxin B Sulfates and Dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 68071-4375-05 NuCare 5 ml — AT FDA listed —
Neomycin Polymyxin B Sulfates and Dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 68788-9702-05 Preferred 1 bottle — AT FDA listed —
Neomycin Polymyxin B Sulfates And Dexamethasone 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 72189-0320-05 DirectRx 5 ml — AT FDA listed —
Maxitrol 3.5 mg/mL; 10000 [USP'U]/mL; 1 mg/mL 82667-0100-05 Harrow 5 ml — AT FDA listed —
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
On the market since
Mar 2025
📍
2026
Currently FDA-listed
1 year listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Dexamethasone / Neomycin / Polymyxin B inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerNordic Pharma, Inc.
Application holderHARROW EYE LLC
FDA applicationNDA050023 (NDA AUTHORIZED GENERIC)
Labeler code69918
First marketedMar 2025
Product typeHuman Prescription Drug
Portfolio15 products on file

More NDCs from Nordic Pharma, Inc. labeler code 69918

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q2 2025 – Q1 2026 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
24.1K
Units reimbursed last 4 qtrs
125.2K
Gross reimbursed last 4 qtrs
$381.8K
Avg / prescription
$15.86
Avg / unit
$3.0483
Latest quarter Q1 2026
6.1KRx
Medicaid pays / mL
$3.0483
gross reimbursed
vs
NADAC / mL
$1.7823
acquisition cost
=
Spread
+$1.2660
+71% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
39% FFS 61% MCO
Fee-for-service · 9,347 Rx Managed care · 14,723 Rx
State Medicaid map
Alaska: no data reported AK Maine: 490 units · 35.1 per 100k residents ME Washington: 830 units · 10.6 per 100k residents WA Idaho: 680 units · 34.6 per 100k residents ID Montana: 65 units · 5.7 per 100k residents MT North Dakota: no data reported ND Minnesota: 3,790 units · 66.1 per 100k residents MN Wisconsin: 2,045 units · 34.6 per 100k residents WI Michigan: 3,925 units · 39.1 per 100k residents MI New York: 5,055 units · 25.8 per 100k residents NY Vermont: 70 units · 10.8 per 100k residents VT New Hampshire: no data reported NH Oregon: 970 units · 22.9 per 100k residents OR Nevada: 1,100 units · 34.4 per 100k residents NV Wyoming: 85 units · 14.6 per 100k residents WY South Dakota: 65 units · 7.1 per 100k residents SD Iowa: 1,090 units · 34.0 per 100k residents IA Illinois: 8,090 units · 64.5 per 100k residents IL Indiana: 850 units · 12.4 per 100k residents IN Ohio: 3,965 units · 33.6 per 100k residents OH Pennsylvania: 1,535 units · 11.8 per 100k residents PA New Jersey: 3,100 units · 33.4 per 100k residents NJ Massachusetts: 910 units · 13.0 per 100k residents MA California: 21,775 units · 55.9 per 100k residents CA Utah: 435 units · 12.7 per 100k residents UT Colorado: 2,700 units · 45.9 per 100k residents CO Nebraska: 1,330 units · 67.2 per 100k residents NE Missouri: 2,170 units · 35.0 per 100k residents MO Kentucky: 3,320 units · 73.4 per 100k residents KY West Virginia: 895 units · 50.6 per 100k residents WV Virginia: 1,060 units · 12.2 per 100k residents VA Maryland: 1,000 units · 16.2 per 100k residents MD Connecticut: 1,910 units · 52.8 per 100k residents CT Rhode Island: 1,355 units · 124 per 100k residents RI Arizona: 2,670 units · 35.9 per 100k residents AZ New Mexico: 4,440 units · 210 per 100k residents NM Kansas: 605 units · 20.6 per 100k residents KS Arkansas: 1,540 units · 50.2 per 100k residents AR Tennessee: 5,575 units · 78.2 per 100k residents TN North Carolina: 6,180 units · 57.0 per 100k residents NC South Carolina: 695 units · 12.9 per 100k residents SC Delaware: 1,315 units · 128 per 100k residents DE Oklahoma: 3,044 units · 75.1 per 100k residents OK Louisiana: 7,370 units · 161 per 100k residents LA Mississippi: 1,970 units · 67.0 per 100k residents MS Alabama: 1,475 units · 28.9 per 100k residents AL Georgia: 705 units · 6.4 per 100k residents GA D.C.: no data reported DC Hawaii: 195 units · 13.6 per 100k residents HI Texas: 6,145 units · 20.1 per 100k residents TX Florida: 4,525 units · 20.0 per 100k residents FL
Units reimbursed · per 100k residents
5.7210
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Mexico 210 /100k
2 Louisiana 161 /100k
3 Delaware 128 /100k
4 Rhode Island 124 /100k
5 Tennessee 78.2 /100k
6 Oklahoma 75.1 /100k
7 Kentucky 73.4 /100k
8 Nebraska 67.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
← 69918-0380-30 · Nordic 69918-0560-30 · Amring →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.